SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
NUVB

Nuvation Bio Inc. (New York Stock Exchange:NUVB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$3.80-$0.01 (-0.26%)
 
Market cap
$1.34B
Insider Score
Health Score
Analyst consensus
Listed since
Aug 26, 2020
Market Cap$1.34B-48.7%
Revenue (ttm)$201.73M+654.2%
Net Income-$135.93M+37.5%
EPS-$0.40+38.2%
Shares Out352.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,848,938
Open$3.76
Previous Close$3.81
Day's Range$3.73 - $3.91
52-Week Range$3.71 - $9.75
Beta1.73
AnalystsBuy
Price Target$17.00(+347.37%)
Earnings DateMar 1, 2027

About NUVB

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

Address
1500 Broadway, New York City, NY, 10036, US
Market Cap
1.34 billion
Employees
310
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$7.46M
Bought
$118.25K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $12.50 (+228.9%)

3 firms rating NUVB in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From NUVB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.26%
5 Days
-4.76%
1 Month
-19.15%
6 Months
-19.49%
1 Year
-48.72%

$NUVB stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in NUVB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by NUVB's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

NUVB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

NUVB Revenue by Segment or Geography

NUVB's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New NUVB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to NUVB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in NUVB

VTIVanguard Morningstar Total Stock Market ETF$33.37M
IWMiShares Russell 2000 ETF$25.63M
VXFVanguard Extended Market ETF$14.28M
IWOiShares Russell 2000 Growth ETF$9.03M
IBBiShares Biotechnology ETF$7.40M
VTWOVanguard Russell 2000 ETF$7.05M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from NUVB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
14.03
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Strong positive clinical data on safusidenib showing 81.5% benefit rate in glioma trial; mixed valuation commentary suggests established investor confidence.

Recent Insider Activity

Buys
1
Sells
12
Buy Value
$118.25K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

XPHState Street SPDR S&P Pharmaceuticals ETF1.24%
BBPVirtus Biotech ETF1.12%
PTHInvesco Dorsey Wright Healthcare Momentum ETF1.08%
SBIOALPS Medical Breakthroughs ETF0.93%
IDNAiShares Genomics Immunology and Healthcare ETF0.93%
CANCTema Oncology ETF0.83%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.37%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.28%
IWCiShares Micro-Cap ETF0.27%
ACSGAmerican Century Small Cap Growth Insights ETF0.23%
IHEiShares U.S. Pharmaceuticals ETF0.23%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.19%

Weight is the stock’s share of each fund’s holdings.